You must be 21 years of age or older to enter Curo. Products and information on this site are intended for laboratory research use only and are not for human or animal use.
Research-use material
Metabolic & Performance$219
The "triple-G" metabolic peptide, studied across GLP-1, GIP, and glucagon pathways for weight, appetite, and body composition.
For laboratory research use only. Not for human or animal consumption.
RTA-GLP3 is the research designation for retatrutide (reta), an investigational peptide that acts on three metabolic receptors at once: GLP-1, GIP, and glucagon. That triple action earned it the "triple-G" nickname, and it has quickly become one of the most closely watched compounds in metabolic and weight research.
Research centers on how the GLP-1 arm curbs appetite and slows stomach emptying, the GIP arm supports insulin response and fat metabolism, and the glucagon arm raises energy expenditure and targets fat stored in the liver. Most studies focus on body weight, body composition, appetite, blood-sugar control, and liver fat. The added glucagon activity is what sets it apart from dual-agonist peptides.
Unlike most research peptides, retatrutide has been through large randomized human trials for obesity and type 2 diabetes, though it remains investigational and is not FDA-approved.
This set includes one CJC-1295 no DAC compound and one Ipamorelin compound. Each compound is packaged separately and is not pre-mixed.
A GHRH-analog and selective-secretagogue pairing, studied together for a larger combined growth-hormone pulse than either compound produces alone.